Peripheral androgen levels in danazol-treated premenopausal women.
Eighteen normally menstruating women with endometriosis were treated with 600 mg of danazol daily for 6 months. Blood samples were taken before and after 2, 4, 8, 12, and 16 weeks of treatment and were analyzed for plasma dehydroepiandrosterone sulfate (DHEA-S), dehydroepiandrosterone (DHEA), and testosterone (T) and for serum alanine aminotransferase (ALAT), albumin, creatinine, potassium, and sodium. The basal values of all parameters studied were well within normal reference limits. DHEA-S was significantly increased at 2, 4, and 8 weeks, and DHEA significantly decreased at 8 and 12 weeks of treatment. The ratio between DHEA and DHEA-S was significantly decreased at weeks 4, 8, 12, and 16. T was significantly decreased during the whole period of observation. ALAT was significantly increased at weeks 4, 8, 12, and 16. A slight but significant increase was observed for creatinine and potassium, while no changes were observed for albumin and sodium. Of the two major androgen sources, the adrenal cortex appears to be relatively unaffected; whereas the ovary may be affected to a minor degree. Therefore, it seems likely that the changes observed in DHEA and DHEA-S may be due to minor alterations in renal and hepatic turnover rather than an effect on adrenal steroidogenesis.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000728:Androgens / Q000097:blood*; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use*; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives / Q000097:blood; D019314:Dehydroepiandrosterone Sulfate; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D011245:Pregnadienes / Q000627:therapeutic use*; D013739:Testosterone / Q000097:blood
D000728:Androgens; D011245:Pregnadienes; D013739:Testosterone; D003687:Dehydroepiandrosterone; D019314:Dehydroepiandrosterone Sulfate; D000410:Alanine Transaminase; D003613:Danazol